Beckman Robert A, Loeb Lawrence A
Departments of Oncology and Biostatistics, Bioinformatics, & Biomathematics, Lombardi Comprehensive Cancer Center and Innovation Center for Biomedical Informatics, Georgetown University Medical Center, Washington, DC 20007 USA.
Joseph Gottstein Memorial Cancer Research Laboratory, Departments of Pathology and Biochemistry, University of Washington School of Medicine, Seattle, WA, 98195 USA.
DNA Repair (Amst). 2017 Aug;56:7-15. doi: 10.1016/j.dnarep.2017.06.002. Epub 2017 Jun 9.
For the last 40 years the authors have collaborated on trying to understand the complexities of human cancer by formulating testable mathematical models that are based on mutation accumulation in human malignancies. We summarize the concepts encompassed by multiple mutations in human cancers in the context of source, accumulation during carcinogenesis and tumor progression, and therapeutic consequences. We conclude that the efficacious treatment of human cancer by targeted therapy will involve individualized, uniquely directed specific agents singly and in simultaneous combinations, and take into account the importance of targeting resistant subclonal mutations, particularly those subclones with alterations in DNA repair genes, DNA polymerase, and other genes required to maintain genetic stability.
在过去40年里,作者们一直合作,试图通过构建基于人类恶性肿瘤中突变积累的可测试数学模型来理解人类癌症的复杂性。我们在来源、致癌过程和肿瘤进展中的积累以及治疗后果的背景下,总结了人类癌症中多重突变所涵盖的概念。我们得出结论,通过靶向治疗有效治疗人类癌症将涉及单独和同时联合使用个体化、独特定向的特定药物,并考虑靶向抗性亚克隆突变的重要性,特别是那些DNA修复基因、DNA聚合酶和维持遗传稳定性所需的其他基因发生改变的亚克隆。